Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

Published : Feb 20, 2025, 09:00 AM ISTUpdated : Feb 21, 2025, 08:00 AM IST
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

Synopsis

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Bausch Health Companies Inc. shares (BHC) jumped over 7% in after-hours trading on Wednesday following a solid fourth-quarter earnings report that beat revenue estimates and reaffirmed strong guidance for 2025.

The company posted Q4 revenue of $2.56 billion, surpassing the consensus estimate of $2.51 billion, while adjusted earnings per share (EPS) of $1.14 narrowly topped expectations of $1.13. 

Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $935 million, up from $869 million a year ago.

CEO Thomas Appio highlighted 2024 as a year of "delivering on our commitments," with results landing at the high end of revenue guidance and exceeding expectations for adjusted EBITDA (excluding Bausch + Lomb) and operating cash flow.

Salix, the company's gastrointestinal and hepatology division, generated $634 million in Q4 revenue, up 9% year-over-year. This was largely driven by Xifaxan, a treatment for irritable bowel syndrome and traveler's diarrhea, which posted 16% growth. 

The Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

For 2025, Bausch Health projects revenue between $9.90 billion and $10.15 billion, above the consensus estimate of $9.89 billion. 

The company also forecasts FY25 adjusted EBITDA between $3.525 billion and $3.675 billion.

Retail sentiment on Stocktwits turned 'extremely bullish' following the earnings report, with message volume spiking 1,900% on Wednesday.

One user highlighted "very good organic revenue growth and solid guidance," expecting a strong bounce for the stock. 

Another hoped for a rally past $20 per share.

However, BHC shares remain about 35% below analysts' average target price of $8.83. 

The stock has lost over 19% year-to-date.  

For updates and corrections, email newsroom[at]stocktwits[dot]com.<

PREV

Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.

Recommended Stories

Gujarat Kidney IPO Draws Rs 100 Crore Support From Anchor Investors
Gold Prices in India Slip Rs 1,000 From Record High; Will Rates Rise Again Before Christmas?